Johnson & Johnson ($JNJ) has signed a deal with ViiV Healthcare, the HIV-focused venture majority-owned by GlaxoSmithKline ($GSK), to spin their two antivirals into a single tablet, potentially sparing patients from some harsh side effects associated with current therapies and challenging Gilead Sciences' ($GILD) dominance in the field. Report